{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:28Z","timestamp":1792783288076,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Society for the Promotion of Science","award":["20K08938"],"award-info":[{"award-number":["20K08938"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03458-5","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:45:41Z","timestamp":1792471541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugates and tumor immunity in breast cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Shinichiro","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"3458_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"3458_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3458_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"3458_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"3458_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"key":"3458_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107.","journal-title":"Nat Rev Immunol"},{"key":"3458_CR7","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, Harper J, Rothstein R, et al. Antibody\u2013drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 2017;77:2686\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2854.","journal-title":"Cancer Res"},{"key":"3458_CR8","doi-asserted-by":"publisher","first-page":"e1565859","DOI":"10.1080\/2162402X.2019.1565859","volume":"8","author":"M Bauzon","year":"2019","unstructured":"Bauzon M, Drake PM, Barfield RM, et al. Maytansine-bearing antibody\u2013drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology. 2019;8:e1565859. https:\/\/doi.org\/10.1080\/2162402X.2019.1565859.","journal-title":"Oncoimmunology"},{"key":"3458_CR9","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody\u2013drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494\u2013503. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0749.","journal-title":"Mol Cancer Ther"},{"key":"3458_CR10","doi-asserted-by":"publisher","first-page":"2220466","DOI":"10.1080\/19420862.2023.2220466","volume":"15","author":"X Tan","year":"2023","unstructured":"Tan X, et al. A HER2-targeted antibody\u2013novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells. MAbs. 2023;15:2220466. https:\/\/doi.org\/10.1080\/19420862.2023.2220466.","journal-title":"MAbs"},{"key":"3458_CR11","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29:2110\u201320. https:\/\/doi.org\/10.1038\/s41591-023-02478-2.","journal-title":"Nat Med"},{"key":"3458_CR12","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin Cancer Res. 2024;30:5548\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1513.","journal-title":"Clin Cancer Res"},{"key":"3458_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394:354\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2508959.","journal-title":"N Engl J Med"},{"key":"3458_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","volume":"31","author":"RA Bukhalid","year":"2025","unstructured":"Bukhalid RA, et al. XMT-2056, a HER2-directed STING agonist antibody\u2013drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin Cancer Res. 2025;31:1766\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2449.","journal-title":"Clin Cancer Res"},{"key":"3458_CR15","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","volume":"15","author":"NM Cetinbas","year":"2024","unstructured":"Cetinbas NM, et al. Tumor cell-directed STING agonist antibody\u2013drug conjugates induce type III interferons and antitumor innate immune responses. Nat Commun. 2024;15:5842. https:\/\/doi.org\/10.1038\/s41467-024-49932-4.","journal-title":"Nat Commun"},{"key":"3458_CR16","doi-asserted-by":"publisher","first-page":"e2214278119","DOI":"10.1073\/pnas.2214278119","volume":"119","author":"YT Wu","year":"2022","unstructured":"Wu YT, et al. Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proc Natl Acad Sci U S A. 2022;119:e2214278119. https:\/\/doi.org\/10.1073\/pnas.2214278119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3458_CR17","doi-asserted-by":"publisher","first-page":"e70254","DOI":"10.1002\/mco2.70254","volume":"6","author":"G Wu","year":"2025","unstructured":"Wu G, Yu C, Ding C, et al. Next-generation HER-2 tumor-targeted delivery of the STING agonist immune-stimulating antibody conjugate improves anticancer efficacy and induces immunological memory. MedComm (2020). 2025;6:e70254. https:\/\/doi.org\/10.1002\/mco2.70254.","journal-title":"MedComm (2020)"},{"key":"3458_CR18","doi-asserted-by":"publisher","first-page":"111647","DOI":"10.1016\/j.cellsig.2025.111647","volume":"128","author":"H Vasiyani","year":"2025","unstructured":"Vasiyani H, Wadhwa B. STING activation and overcoming the challenges associated with STING agonists using ADC and other delivery systems. Cell Signal. 2025;128:111647. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111647.","journal-title":"Cell Signal"},{"key":"3458_CR19","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015;194:4595\u2013603. https:\/\/doi.org\/10.4049\/jimmunol.1403014.","journal-title":"J Immunol"},{"key":"3458_CR20","doi-asserted-by":"publisher","first-page":"112767","DOI":"10.1016\/j.jim.2020.112767","volume":"480","author":"J Zhang","year":"2020","unstructured":"Zhang J, Vernes JM, Wen X, Oh E, Scales SJ, Meng YG. Reproducible quantification of IgG uptake at endogenous and overexpressed FcRn levels at pH 7.4: comparison of a wild type IgG and a stronger FcRn binding variant. J Immunol Methods. 2020;480:112767. https:\/\/doi.org\/10.1016\/j.jim.2020.112767.","journal-title":"J Immunol Methods"},{"key":"3458_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential mechanisms of target-independent uptake and toxicity of antibody\u2013drug conjugates. Pharmacol Ther. 2019;200:110\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008.","journal-title":"Pharmacol Ther"},{"key":"3458_CR22","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1021\/acs.molpharmaceut.6b00153","volume":"13","author":"KJ Hamblett","year":"2016","unstructured":"Hamblett KJ, Le T, Rock BM, et al. Altering antibody\u2013drug conjugate binding to the neonatal Fc receptor impacts efficacy and tolerability. Mol Pharm. 2016;13:2387\u201396. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00153.","journal-title":"Mol Pharm"},{"key":"3458_CR23","unstructured":"Creative Biolabs. Uptake and potential toxicity mechanism of non-target-dependent ADC\u2014III. Published May 8. 2023. Accessed August 31, 2026. https:\/\/www.creative-biolabs.com\/adc\/uptake-and-potential-toxicity-mechanism-of-non-target-dependent-adc-iii.htm"},{"key":"3458_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive HER2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285\u201396. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"key":"3458_CR25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002.","journal-title":"Ann Oncol"},{"key":"3458_CR26","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino MC, Sands J, Paz-Ares L, et al. PL02.11 Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. J Thorac Oncol. 2024;19:S2\u20133. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.015.","journal-title":"J Thorac Oncol"},{"key":"3458_CR27","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan, a HER3-directed antibody\u2013drug conjugate, in patients with previously treated HER3-expressing metastatic breast cancer: a multicenter phase I\/II trial. J Clin Oncol. 2023;41:5550\u201360. https:\/\/doi.org\/10.1200\/JCO.23.00882.","journal-title":"J Clin Oncol"},{"key":"3458_CR28","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Mosele F, Corcos N, et al. Patritumab deruxtecan in HR-positive\/HER2-negative advanced breast cancer: a phase 2 trial. Nat Med. 2025;31:3492\u2013503. https:\/\/doi.org\/10.1038\/s41591-025-03885-3.","journal-title":"Nat Med"},{"key":"3458_CR29","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1074\/mcp.O115.049049","volume":"14","author":"C Steiner","year":"2015","unstructured":"Steiner C, Tille JC, Lamerz J, et al. Quantification of HER2 by targeted mass spectrometry in formalin-fixed paraffin-embedded breast cancer tissues. Mol Cell Proteom. 2015;14:2786\u201399. https:\/\/doi.org\/10.1074\/mcp.O115.049049.","journal-title":"Mol Cell Proteom"},{"issue":"4 Suppl","key":"3458_CR30","doi-asserted-by":"publisher","first-page":"PD6","DOI":"10.1158\/1538-7445.SABCS20-PD6-01","volume":"81","author":"M Gustavson","year":"2021","unstructured":"Gustavson M, et al. Novel approach to HER2 quantification: digital image analysis-based quantitative continuous scoring and prediction of response to trastuzumab deruxtecan. Cancer Res. 2021;81(4 Suppl):PD6\u201301. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PD6-01.","journal-title":"Cancer Res"},{"key":"3458_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41698-026-01365-6","volume":"10","author":"P Tarantino","year":"2026","unstructured":"Tarantino P, Kim SE, Hughes ME, et al. Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. NPJ Precis Oncol. 2026;10:141. https:\/\/doi.org\/10.1038\/s41698-026-01365-6.","journal-title":"NPJ Precis Oncol"},{"key":"3458_CR32","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei Q, Yang T, Zhang Z, et al. Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment. Cancer Res. 2025;85:2081\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2021.","journal-title":"Cancer Res"},{"key":"3458_CR33","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan-related interstitial lung disease\/pneumonitis: focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378.","journal-title":"Cancer Treat Rev"},{"key":"3458_CR34","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7:100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03458-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:15Z","timestamp":1792515735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03458-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03458-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, ChatGPT (OpenAI) was used to support English-language editing, manuscript organization, consistency checking, and preparation of schematic figure layouts. No generative image model was used. All AI-assisted outputs, references, scientific interpretations, and figures were critically reviewed and verified by the author, who assumes full responsibility for the final content.","order":4,"name":"Ethics","label":"Use of artificial intelligence tools","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"345"}}